LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

MRK

116.3

+0.48%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

MRK

116.3

+0.48%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

MRK

116.3

+0.48%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

MRK

116.3

+0.48%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

MRK

116.3

+0.48%↑

Home・Akciju saraksts・Editas Medicine Inc

Editas Medicine Inc

Slēgts

SektorsVeselības aprūpe

2.24 -6.28

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.22

Max

2.38

Galvenie mērījumi
By Trading Economics
Ienākumi	19M -5.6M
Pārdošana	17M 25M
EPS	-0.06
Peļņas marža	-22.715
Darbinieki	87
EBITDA	165M 143M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+114.58% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	8.4M 235M
Iepriekšējā atvēršanas cena	8.52
Iepriekšējā slēgšanas cena	2.24

Ziņu noskaņojums

By Acuity

20%

80%

37 / 350 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.33 / 1.54 Atbalsts un pretestība

Editas Medicine Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. marts 18:58 UTC

Galvenie tirgus virzītāji

MDA Space Shares Drop After NASA Shifts Focus to Moon's Surface and Away From Space Station

2026. g. 24. marts 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 24. marts 23:48 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

2026. g. 24. marts 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rises, Boosted by Dollar Weakness -- Market Talk

2026. g. 24. marts 23:16 UTC

Tirgus saruna

Venezuelan Opposition Leader Says Oil Output Could Reach 5 Million B/D -- Market Talk

2026. g. 24. marts 22:40 UTC

Peļņas

Shanghai Fosun Pharmaceutical: Results Supported by Higher Rev From Innovative Drugs, Overseas Business >2196.HK

2026. g. 24. marts 22:40 UTC

Peļņas

Shanghai Fosun Pharmaceutical 2025 Net CNY3.37B Vs. Net CNY2.77B >2196.HK

2026. g. 24. marts 22:40 UTC

Peļņas

Shanghai Fosun Pharmaceutical 2025 Rev CNY41.50B Vs. CNY40.91B >2196.HK

2026. g. 24. marts 21:44 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 24. marts 21:44 UTC

Tirgus saruna

Sandfire's New Bull Excited by Kalkaroo Copper Deposit -- Market Talk

2026. g. 24. marts 20:59 UTC

Peļņas

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

2026. g. 24. marts 20:58 UTC

Galvenie ziņu notikumi

Israel Hits Russian-Iranian Weapons Smuggling Route in the Caspian Sea -- WSJ

2026. g. 24. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Energy & Utilities Roundup: Market Talk

2026. g. 24. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 24. marts 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 24. marts 20:25 UTC

Peļņas

This Palantir-Linked Drone Stock Was Flying Under the Radar -- Until Now -- Barrons.com

2026. g. 24. marts 20:15 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Commodities Roundup: Market Talk

2026. g. 24. marts 20:10 UTC

Tirgus saruna

Canada Mortgage Arrears Linked to Labor Market Performance -- Market Talk

2026. g. 24. marts 20:10 UTC

Peļņas

Worthington Enterprises 3Q Sales $378.7M >WOR

2026. g. 24. marts 20:10 UTC

Peļņas

Worthington Enterprises 3Q Adj EPS 98c >WOR

2026. g. 24. marts 20:10 UTC

Peļņas

Worthington Enterprises 3Q EPS 92c >WOR

2026. g. 24. marts 19:25 UTC

Tirgus saruna

Galvenie ziņu notikumi

Canada Needs Roughly 100 Days to Meet IEA's Oil-Stock Release -- Market Talk

2026. g. 24. marts 19:06 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Regain Ground As Strikes Continue in Middle East -- Market Talk

2026. g. 24. marts 18:51 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Settles Higher As Oil Futures Gain -- Market Talk

2026. g. 24. marts 18:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 24. marts 18:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Mideast Conflict to Hobble But Not Derail Canadian Economy -- Market Talk

2026. g. 24. marts 18:34 UTC

Galvenie ziņu notikumi

Oil Production in the Middle East Will Take Months to Come Back, CEO says. Why $100 Oil Could Be Here to Stay. -- Barrons.com

2026. g. 24. marts 18:27 UTC

Tirgus saruna

Inflation Pickup Could Keep Bank of Mexico on Hold -- Market Talk

2026. g. 24. marts 18:21 UTC

Tirgus saruna

Galvenie ziņu notikumi

Silver Snaps 9-Session Losing Streak -- Market Talk

2026. g. 24. marts 18:00 UTC

Iegādes, apvienošanās, pārņemšana

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Editas Medicine Inc Prognoze

Cenas mērķis

By TipRanks

114.58% augšup

Prognoze 12 mēnešiem

Vidējais 5.15 USD 114.58%

Augstākais 8 USD

Zemākais 4 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Editas Medicine Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Editas Medicine Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.33 / 1.54Atbalsts un pretestība

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Noskaņojums

By Acuity

37 / 350 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.